NATTO: OPTIONS GRANTED
Oslo, Norway (13 February 2019) — Based on the power of attorney granted at the annual general meeting of NattoPharma ASA ("NattoPharma" or "Company") on May 30th, 2018, and the option program related to defined operational objectives approved by the Board of Directors in 2018, the Board of Directors of NattoPharma has in board proceedings February 12th, 2019 granted a total of 292 500 options to executive management, other employees and strategic partners. Options are granted based on performance against defined criteria and metrics.
The following persons on the executive management team have been granted options;
| Name | Granted Options | Options Prior to Grant | Options after Grant |
| Kjetil Ramsøy, CEO & CFO | 100 000 | 125 100 | 225 100 |
Other employees and partners have been granted a total of 192 500 options.
The options have an exercise price equal the closing price on Oslo Axess on February 12th, 2019, which is equal to NOK 9,00.
The options granted are vested immediately and may be exercised up to and including March 31st, 2023.
X X X
For more information, please contact:
Kjetil Ramsøy,
CEO, NattoPharma
E-mail: kjetil.ramsoy@nattopharma.com
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.